Comparison
Alpha-GPC vs Semaglutide
Side-by-side of Alpha-GPC and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-GPC
Alpha GPC supplement profile: 300 to 600 mg dosage, acetylcholine synthesis, attention and reaction-time evidence, side effects, and choline donor comparisons.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Effects at a glance
Alpha-GPC
- •Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
- •Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
- •Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
- •ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
- •Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
- •TMAO production raises a contested cardiovascular concern at chronic high doses
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Side-by-side
| Attribute | Alpha-GPC | Semaglutide |
|---|---|---|
| Category | supplement | pharmaceutical |
| Also known as | L-Alpha glycerylphosphorylcholine, choline alfoscerate, GPC, alpha-glyceryl phosphorylcholine | Ozempic, Wegovy, Rybelsus |
| Half-life (hr) ↗ | 4 | 168 |
| Typical dose (mg) ↗ | 600 | 2.4 |
| Dosing frequency | 1 to 3 times daily | weekly (SC); daily (oral Rybelsus) |
| Routes | oral | subcutaneous, oral |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 2 | 72 |
| Molecular weight | 257.22 | 4113.58 |
| Molecular formula | C8H20NO6P | - |
| Mechanism | Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS. | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. |
| Legal status | Dietary supplement (US); prescription medication in much of Europe | Prescription only (FDA-approved, EMA-approved) |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) |
| Pregnancy | Insufficient data; choline generally recommended in pregnancy | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 28319-77-9 | 910463-68-2 |
| PubChem CID | 71920 | 56843331 |
| Wikidata | Q411478 | Q27089394 |
Safety profile
Alpha-GPC
Common side effects
- mild GI upset
- headache
- dizziness
- occasional insomnia with evening dosing
Contraindications
- established cardiovascular disease (TMAO concern)
- concurrent strong anticholinergic therapy
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors (donepezil): additive cholinergic effect, basis for ASCOMALVA protocol(minor)
- scopolamine: partial counteraction of anticholinergic effect(minor)
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Alpha-GPC comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Semaglutide is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Alpha-GPC.
- → If your priority is athletic performance, pick Alpha-GPC.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
Edge case: If you want to avoid prescription-only, Alpha-GPC is the more accessible choice.
Default choice: Alpha-GPC. Lower friction to source, and broader goal coverage. Reach for Semaglutide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-GPC and Semaglutide?
Alpha-GPC and Semaglutide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-GPC or Semaglutide?
Alpha-GPC half-life is 4 hours; Semaglutide half-life is 168 hours.
Can you stack Alpha-GPC with Semaglutide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper